Net Deals Web Search

Search results

  1. Results From The WOW.Com Content Network
  2. US FDA approves Novartis' kidney disease drug - AOL

    www.aol.com/news/us-fda-approves-novartis-kidney...

    August 7, 2024 at 2:23 PM. By Sriparna Roy. (Reuters) -The U.S. Food and Drug Administration has approved the use of Novartis' drug to reduce excess protein in the urine of patients with a type of ...

  3. Pfizer–BioNTech COVID-19 vaccine - Wikipedia

    en.wikipedia.org/wiki/Pfizer–BioNTech_COVID-19...

    The Pfizer–BioNTech COVID-19 vaccine, sold under the brand name Comirnaty, [2] [32] is an mRNA-based COVID-19 vaccine developed by the German biotechnology company BioNTech. For its development, BioNTech collaborated with the American company Pfizer to carry out clinical trials, logistics, and manufacturing. [44] [45] It is authorized for use ...

  4. Novartis - Wikipedia

    en.wikipedia.org/wiki/Novartis

    Novartis AG. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...

  5. List of largest pharmaceutical mergers and acquisitions

    en.wikipedia.org/wiki/List_of_largest...

    1. 2015. Pfizer. Allergan, plc. 160. 206. In November 2015 Pfizer announced it would acquire Allergan, plc for $160 billion ($206 billion, adjusted for inflation). However, this deal was cancelled in April 2016 due to new US tax inversion rules. [12] [13] Had this transaction been completed, this would have been the largest within this industry.

  6. Novartis to acquire cancer-focused MorphoSys for $2.9 billion

    www.aol.com/news/novartis-acquire-cancer-drug...

    (Reuters) -Drugmaker Novartis AG said it will acquire MorphoSys AG, a developer of cancer treatments, for 2.7 billion euros ($2.9 billion), adding a promising rare bone-marrow cancer treatment ...

  7. Novartis' Sandoz targets biosimilar version of J&J drug in ...

    www.aol.com/news/novartis-sandoz-targets-bio...

    Novartis shareholders are due to vote on the Sandoz spin-off at an extraordinary general meeting on Sept. 15, with the first day of trading scheduled for Oct 4.

  8. Brolucizumab - Wikipedia

    en.wikipedia.org/wiki/Brolucizumab

    In October 2019, Novartis announced that the US Food and Drug Administration (FDA) approved brolucizumab injection for the treatment of wet age-related macular degeneration. [ 7 ] The FDA approved brolucizumab based on evidence from two clinical trials (Trial 1/ NCT02307682 and Trial 2/NCT02434328) of 1459 participants, 50–97 years old, with ...

  9. Vasant Narasimhan - Wikipedia

    en.wikipedia.org/wiki/Vasant_Narasimhan

    Vasant "Vas" Narasimhan (born August 26, 1976) is an American physician and the chief executive officer of Novartis. [1] [2] [3] [4] He succeeded Joseph Jimenez who ...